| Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function (NCT07751250) | Arcus Biosciences, Inc. | 2026-08-01 |
| A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants (NCT07662057) | Arcus Biosciences, Inc. | 2026-07-01 |
| A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants (NCT07641881) | Arcus Biosciences, Inc. | 2026-05-29 |
| Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24) (NCT07364214) | Arcus Biosciences, Inc. | 2026-02-03 |
| Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma (NCT07011719) | Arcus Biosciences, Inc. | 2025-09-08 |
| Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29) (NCT06919991) | Arcus Biosciences, Inc. | 2025-05-02 |
| Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (NCT06608927) | Arcus Biosciences, Inc. | 2024-12-13 |
| A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (NCT06120075) | Arcus Biosciences, Inc. | 2024-01-19 |
| A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers (NCT06004921) | Arcus Biosciences, Inc. | 2023-10-16 |
| Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (NCT05891171) | Arcus Biosciences, Inc. | 2023-10-13 |
| A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers (NCT05999513) | Arcus Biosciences, Inc. | 2023-08-21 |
| A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (NCT05568095) | Arcus Biosciences, Inc. | 2022-11-21 |
| A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors (NCT05536141) | Arcus Biosciences, Inc. | 2022-10-26 |
| A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies (NCT05329766) | Arcus Biosciences, Inc. | 2022-06-10 |
| A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer (NCT05411146) | Arcus Biosciences, Inc. | 2022-05-25 |
| A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants (NCT05277012) | Arcus Biosciences, Inc. | 2022-02-10 |
| Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers (NCT05117554) | Arcus Biosciences, Inc. | 2021-11-09 |
| A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants (NCT05154136) | Arcus Biosciences, Inc. | 2021-10-20 |
| An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. (NCT04660812) | Arcus Biosciences, Inc. | 2021-05-10 |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (NCT04772989) | Arcus Biosciences, Inc. | 2021-03-19 |
| Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (NCT04736173) | Arcus Biosciences, Inc. | 2021-02-08 |
| A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers (NCT04575311) | Arcus Biosciences, Inc. | 2020-10-20 |
| Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (NCT04381832) | Arcus Biosciences, Inc. | 2020-07-07 |
| Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (NCT04262856) | Arcus Biosciences, Inc. | 2020-05-28 |
| A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies (NCT04104672) | Arcus Biosciences, Inc. | 2019-11-06 |
| Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors (NCT04087018) | Arcus Biosciences, Inc. | 2019-09-24 |
| A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer (NCT03846310) | Arcus Biosciences, Inc. | 2019-04-01 |
| A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies (NCT03720678) | Arcus Biosciences, Inc. | 2018-11-18 |
| A Study to Investigate the Safety of AB680 in Healthy Volunteers (NCT03677973) | Arcus Biosciences, Inc. | 2018-10-16 |
| A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies (NCT03719326) | Arcus Biosciences, Inc. | 2018-10-15 |
| A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies (NCT03628677) | Arcus Biosciences, Inc. | 2018-09-12 |
| A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies (NCT03629756) | Arcus Biosciences, Inc. | 2018-07-24 |